What is WW's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for WW year over year?

What were the key takeaways from WW’s earnings call?

What guidance did WW's management provide for the next earnings period?

What is WW's gross profit margin?

What were the key takeaways from WW's earnings call?

What factors drove the changes in WW's revenue and profit?

Did WW beat or miss consensus estimates last quarter?

- **Clinical Dominance**: Med+ ARPU is 4x higher than behavioral, with 100% YoY growth in clinical subscribers (excluding compounded semaglutide). 50% of new Med+ members are brand-new.
- **Engagement Surge**: Virtual workshop attendance up 30% YoY, with physician-led sessions doubling engagement.
- **2026 Guidance**: Revenue $620M-$635M, EBITDA $105M-$115M, driven by clinical expansion and brand repositioning.
- **GLP-1 Success**: Members using GLP-1 Success program lose 29% more weight at 12 months than those on medication alone.

**【CEO Summary Section】**
- **Transformation Progress**: Post-Chapter 11, WeightWatchers has reinvented itself as an integrated weight health ecosystem, combining behavioral programs with clinical care (e.g., GLP-1 medications). Q4 2025 and Q1 2026 momentum validates this strategy.
- **Med+ Growth**: 50% of new Med+ members in Q1 2026 were new to the brand, reflecting successful brand repositioning. ARPU for clinical business is 4x higher than behavioral.
- **Member Engagement**: Virtual workshop attendance among Core+ members increased 30% YoY, with sessions led by affiliated physicians doubling attendance.
- **GLP-1 Success Program**: Members using the program lost 29% more weight at 12 months than those on medication alone, highlighting the value of behavioral support.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Total revenue $163M (-12% YoY), driven by 32% clinical revenue growth offsetting 17% behavioral decline. ARPU rose 8% to $18.73, supported by higher clinical ARPU.
- **2026 Outlook**: Revenue guidance $620M-$635M, adjusted EBITDA $105M-$115M. Marketing spend front-loaded in Q1 ($40M of annual $100M+), with focus on Med+ awareness.
- **Subscriber Trends**: Clinical subscribers expected to reach ~200K by Q1 end (100% YoY growth, excluding compounded semaglutide). Behavioral subscribers ~2.45M (-26% YoY), but 30% of clinical sign-ups transition from behavioral.

**【Q&A Key Highlights】**
- **GLP-1 Demand**: Launch of new oral GLP-1 pill exceeded expectations, with 72% of Med+ members reporting side effect reduction. Q1 2026 clinical subscribers ~200K (100% YoY growth vs. 2025 without compounded semaglutide).
- **New Member Demographics**: 50% of Med+ new members are brand-new, driven by brand repositioning as a clinical leader. Younger members and lapsed behavioral members are returning.
- **Contract Lengths**: 12-month LTC adoption rising in both clinical and behavioral businesses, signaling longer-term engagement.
- **B2B Growth**: Pipeline momentum with UnitedHealth and Rx Flex Fund, though still small-scale. Focus on employer partnerships to diversify revenue.


WW International, Inc.(WW)-20260316-2025 Q4 Earnings call transcript

- **Clinical Growth**: 35% YoY revenue increase, 60% YoY subscriber growth, and 19%-26% weight loss success rates.
- **Digital Transformation**: 2026 app/website redesign to unify medical and behavioral programs with AI.
- **Partnerships**: Amazon Pharmacy, NovoCare, and LillyDirect for medication access and delivery.
- **Menopause Program**: Targets 1.3M U.S. women, with strong early engagement.
- **Challenges**: Behavioral subscribers down 20% YoY, but improving from Q2 lows.
- **Upcoming Catalysts**: Oral GLP-1 launch in early 2026 and peak season marketing push.

**【CEO Summary Section】**
- Emphasized integration of medical solutions (e.g., GLP-1 medications) with traditional behavioral programs, achieving 19%-23% weight loss for clinic members vs. 12% for competitors.
- Launched WeightWatchers Clinic (formerly Weekend Health) and Menopause program, targeting 1.3M U.S. women annually.
- Announced app and website redesign for 2026, aiming to unify clinical and behavioral experiences with AI-driven personalization.
- Highlighted strategic partnerships with Novo Nordisk, LillyDirect, and Amazon Pharmacy for medication access and delivery.

**【CFO Financial Commentary】**
- Q3 2025 Revenue: $172M (-11% YoY), with clinical revenue up 35% YoY and behavioral down 16% YoY.
- Clinical subscribers: 124K (+60% YoY), behavioral subscribers: 2.9M (-20% YoY).
- Adjusted EBITDA: $43M (24.9% margin), cash: $170M, and $100M annual run-rate savings.
- ARPU: $18.52 (+9% YoY), driven by clinical mix shift.
- Q4 2025 outlook: Higher marketing spend for peak season, potential EBITDA decline.

**【Q&A Key Highlights】**
- **App Launch**: First version expected early 2026, with modern UI and integrated clinical/behavioral tools.
- **Retention**: Clinic retention exceeded expectations, with 20% of compounded semaglutide users transitioning to branded/oral meds.
- **Menopause Program**: Targeting new and lapsed members, with Queen Latifah campaign boosting brand visibility.
- **GLP-1 Landscape**: Anticipated oral medication launch in early 2026 as key growth driver.
- **Challenges**: Behavioral business still facing headwinds, but improving from Q2 lows.

**【Strategic Priorities】**
- Unified digital experience with AI-driven personalization.
- Expanded medical business (e.g., GLP-1 Companion Program, cash-pay dietitians).
- Brand modernization and value-based pricing strategy.
- Operational efficiency improvements (e.g., AI voice support, clinical/behavioral integration).

WW International, Inc. (WW) Q3 2025 Earnings Call Transcript

- **Financial Restructuring Success**: 70% debt reduction frees $50M annually, enabling strategic reinvestment.
- **Clinical Growth Driver**: 56% YoY Clinical subscriber growth, with 11% weight loss improvement from integrated GLP-1 program.
- **ARPU Expansion**: +12% YoY to $1.08, driven by higher-margin Clinical mix.
- **Challenges Ahead**: 17% YoY subscriber decline due to compounding semaglutide phase-out, with 80% of those members expected to churn.
- **Strategic Initiatives**: Launching menopause program and expanding B2B partnerships for long-term growth.

**【CEO Opening Remarks】**
- **Debt Restructuring Success**: Reduced debt by 70%, freeing $50M annually in interest savings. Relisted on NASDAQ under ticker WW.
- **Strategic Reorganization**: Completed Chapter 11 emergence, positioning for long-term growth with $100M in run-rate cost savings.
- **Four Core Pillars**: Unified member experience, emerging revenue streams, brand revitalization, and operational excellence.

**【CEO Strategic Initiatives】**
- **Clinical Care Expansion**: 56% YoY growth in Clinical subscribers, integrating GLP-1 medications with behavioral programs. 11% weight loss improvement when combining meds with WW program.
- **New Leadership**: Hired Julie Rice (Chief Experience Officer) and Dr. Kim Boyd (Chief Medical Officer) to drive innovation in community engagement and clinical care.
- **Women's Health Program**: Launching menopause program blending behavior change, community support, and clinical care, targeting women's health market.

**【CFO Financial Highlights】**
- **Revenue Performance**: Q2 revenue $189M (-6% YoY), driven by 13% decline in behavioral business offset by 55% Clinical growth (primarily compounded semaglutide).
- **ARPU Growth**: +12% YoY to $1.08, driven by Clinical mix (5x ARPU of behavioral).
- **Profitability**: Adjusted EBITDA margin 34% (vs. 24.7% prior year), reflecting cost discipline and reduced marketing spend.
- **Cash Position**: $152M cash post-restructuring, with $45M transaction costs and $30M interest payments.

**【Q&A Key Highlights】**
- **Semaglutide Transition Impact**: Q2 subscribers declined 17% YoY, with 56% Clinical growth offset by 5% QoQ decline due to compounded semaglutide phase-out. 80% of compounding members expected to churn by end-2025.
- **B2B Channel Momentum**: Rebuilding relationships with employers/payers, e.g., UnitedHealthcare and Florida Dept. of Health. Longer sales cycle but lower acquisition cost.
- **Women's Health Expansion**: Menopause program to launch late 2025, leveraging existing infrastructure and clinical expertise for curated solutions.


WW International, Inc. (WW) Q2 2025 Earnings Call Transcript

- **Clinical Business Breakout**: Q4 2024 Clinical subscribers +38% YoY to 92,000, driven by compounded semaglutide access and 58% revenue growth.
- **Gross Margin Strength**: Near-record 69.1% Q4 gross margin, 27.4% EBITDAS margin highlights cost savings success.
- **2025 Challenges & Opportunities**: $45M revenue headwind vs. $100M cost savings, 53-week year adds $2-3M EBITDAS pressure, but B2B partnerships (Labcorp 11%+, CVS employer adoption) offer long-term growth.
- **AI-Driven Engagement**: 2M+ meals tracked via AI scanner, 1M+ recipe imports show early reengagement success in Behavioral business.
- **Debt Restructuring Critical**: $100M annual interest expense limits growth; successful debt talks could unlock strategic investments.

**【CEO Opening Remarks】**
- Q4 2024 revenue declined 10% YoY to $184M, driven by a 12% drop in Digital + Workshop subscribers (3.3M total) and a 58% surge in Clinical revenue.
- Clinical subscribers grew 18% QoQ to 92,000, with NPS and retention metrics improving due to compounded semaglutide access.
- 2025 priorities: stabilize business, integrate Clinical & Behavioral programs, enhance member experience through AI-driven features (e.g., food scanner, macro tracking).
- 2025 headwinds: $45M revenue decline from 2024 subscriber base, but $100M cost savings on track (90%+ achieved).

**【CFO Financial Highlights】**
- Full year 2024 revenue: $786M (-12% YoY), with adjusted EBITDAS of $198M (25.4% margin).
- Q4 2024: $50M EBITDAS (27.4% margin), near-record 69.1% gross margin.
- Cash position: $53M at year-end, with $175M revolver drawn for liquidity.
- 2025 challenges: 53-week fiscal year adds $2-3M EBITDAS pressure, $100M annual interest expense constraining growth.

**【Q&A Key Takeaways】**
1. **Clinical Growth Sustainability**: 92K Q4 subscribers (+38% YoY), 18% QoQ growth. Generic semaglutide adoption offset branded shortages, but FDA lifting semaglutide shortage may reduce reliance on compounding.
2. **Behavioral Business Struggles**: Digital + Workshop subscribers down 12% YoY, but 2M+ meals tracked via AI scanner and 1M+ recipe imports show engagement improvement.
3. **Financial Flexibility**: $175M revolver provides liquidity, but leverage remains a key constraint. No Q&A on debt restructuring discussions.
4. **Marketing Efficiency**: Q1 2025 CAC elevated due to peak season, but LTV/CAC improving. 2025 marketing strategy to focus on high-ROI channels.
5. **B2B Expansion**: Labcorp utilization 11%+, CVS partnership driving employer adoption. 2025 B2B growth potential offset by long sales cycles.

**【2025 Outlook】**
- Revenue headwinds from 2024 subscriber decline, but Clinical growth and cost savings (>$100M run rate) support profitability.
- Gross margin expected to remain near 69% as consumer products wind-down benefits persist.
- Free cash flow generation ($113M 2024 ex-restructuring) to be reinvested in growth initiatives if debt restructuring succeeds.

Actual																															14.43	-5.76	-0.58
Forecast																															-0.025	0.51	-0.935
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+57820.00%	-1229.41%	+37.97%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	189.00M	172.09M	162.81M
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	178.05M	161.38M	149.80M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+6.15%	+6.64%	+8.69%

WW

WW fundamentals

WW Q4 2025 Earnings

Earnings Call

You can ask Aime

WW

WW fundamentals

WW Q4 2025 Earnings

Earnings Call

WW Earnings Call Summary for Q4/20258:30 AM on Mar 16, 2026

WW Earnings Call Summary for Q3/20258:30 AM on Nov 6, 2025

WW Earnings Call Summary for Q2/20258:30 AM on Aug 11, 2025

WW Earnings Call Summary for Q4/20245:00 PM on Feb 27, 2025

WW Earnings Call Summary for Q3/20248:30 AM on Nov 6, 2024

You can ask Aime